Active Clinical Trials | LifeBridge Health

All Clinical Trials

Below is a list of all clinical trials, conducted by several of our specialty service lines. You may filter the list of trials by clicking the "Department" dropdown menu and selecting the area that you want to view or that pertains to you.

Clicking "Learn More" may either take you to more information about our departments that conduct the research, or to the official clinicaltrials.gov page for more information about the trial.

COMPLETED - Silent Cerebral Infarct Transfusion Multi-Center Clinical Trial (SIT)

Study # NCT00072761 Date Opened: 12/01/2004

COMPLETED - Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of MST-188 (Purified Poloxamer 188) Injection in Subjects With Sick

Study # NCT01737814 Date Opened: 05/01/2013

COMPLETED - Stroke Prevention Trial in Sickle Cell Anemia (STOP II)

Study # NCT00006182 Date Opened: 07/09/2000

A191901: OPTIMIZING ENDOCRINE THERAPY THROUGH MOTIVATIONAL INTERVIEWING AND TEXT INTERVENTIONS

Study # A191901 Date Opened: 02/15/2021 Principal Investigator: Qiwei Gai

Gynecologic Cancer

INTEGRATED CANCER REPOSITORY FOR CANCER RESEARCH (iCaRe2)

Study # BCCR/iCARE2 Date Opened: 11/01/2013 (All Centers) Principal Investigator: Qiwei Gai

A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigator’s Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Pa

Study # D7630C00001 Date Opened: 11/23/2023 Principal Investigator: Wilfred Layne

OptimICE-pCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy

Study # A012103 Date Opened: 06/14/2023 Principal Investigator: Qiwei Gai

Hematologic Cancer

A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide(CC-92480), Bortezomib, and Dexamethasone (MeziVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM)

Study # NCT05519085 Date Opened: 09/20/2022 Principal Investigator: Qiwei Gai

Supportive Cancers

Blinded Reference Set for Multicancer Early Detection Blood Tests

Study # A212102 Date Opened: 08/30/2022 (All Centers) Principal Investigator: Qiwei Gai

A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy

Study # GS-US-595-6184 Date Opened: 12/12/2022 Principal Investigator: Wilfred Layne

A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤

Study # NRG-BR009 Date Opened: 08/31/2023 (All Centers) Principal Investigator: Wilfred Layne

Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive/Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer

Study # S2206 Date Opened: 11/27/2023 (Sinai & WKRCC) Principal Investigator: Qiwei Gai

The CompassHER2 trials (COMprehensive use of Pathologic Response ASSessment to optimize therapy in HER2-positive breast cancer): CompassHER2 Residual Disease (RD), a double-blinded, phase III randomized trial of T-DM1 and placebo compared with T-DM1 and t

Study # A011801 Date Opened: 05/06/2023 (All Centers) Principal Investigator: Qiwei Gai

Supportive Cancers

WF2304-A172401, Complementary Options for Symptom Management In Cancer (COSMIC): Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics

Study # NCT06418204 Date Opened: 01/30/2025 Principal Investigator: Pallavi Kumar, M.D.

Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) versus Fractionated SRS (FSRS) for Intact Brain Metastases

Study # NRG-BN013 Principal Investigator: David Perry, M.D. Sponsor: dav

NRG-CC014, Radiation Therapy for High-Risk Asymptomatic Bone Metastases: A Pragmatic Multicenter Randomized Phase 3 Clinical Trial (PREEMPT) (NCT06745024)

Study # NRG-CC014 Date Opened: 06/09/2025 Closing Date: 10/01/2028 Principal Investigator: Jason T. Shumadine, M.D. Sponsor: NRG Oncology

NRG-LU008, Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer

Study # NRG-LU008 Date Opened: 07/12/2023 Closing Date: 10/15/2031 Principal Investigator: David Perry, M.D. Sponsor: NRG Oncology

Brain, Breast Cancer, GI, GU, Melanoma

NRG-BN013, Phase III Trial of Single Fraction Stereotactic Radiosurgery (SRS) versus Fractionated SRS (FSRS) for Intact Brain Metastases

Study # NRG-BN013 Date Opened: 12/12/2024 Closing Date: 06/30/2028 Principal Investigator: David Perry, M.D. Sponsor: NRG Oncology